The frequency of EGFR And KRAS mutations in the Turkish population with non-small cell lung cancer and their response to erlotinib therapy
, , , , , , , und | 31. Dez. 2018
Über diesen Artikel
Article Category: Original Article
Online veröffentlicht: 31. Dez. 2018
Seitenbereich: 21 - 26
DOI: https://doi.org/10.2478/bjmg-2018-0022
Schlüsselwörter
© 2018 Demiray A, Yaren A, Karagenç N, Bir F, Demiray AG, Karagür ER, Tokgün O, Elmas L, Akça H, published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
Figure 1
Figure 2
Clinicopathological characteristics of the patients.
| Characteristics | Patients ( |
|---|---|
| Age: | |
| ≤62 years | 148 (49.3) |
| ≥62 years | 152 (50.7) |
| Gender: | |
| males | 238 (50.7) |
| females | 62 (20.7) |
| Smoking habit: | |
| smoker | 233 (74.3) |
| never smoked | 77 (25.7) |
| Histological type: | |
| adenocarcinoma | 228 (76.0) |
| squamous | 62 (20.7) |
| other | 10 (3.3) |
| Stage: | |
| early (I; II; IIIA) | 70 (23.3) |
| advanced (IIIB; IV) | 230 (76.7) |
(A) Types of EGFR mutations in Turkish NSCLC patients.
| Mutation | Exon | Nucleotide Number | Amino Acid Changes | Mutation |
|---|---|---|---|---|
| Point mutation | 18 | 2155 (G>T) | G719C | 1 (0.8%) |
| Point mutation | 18 | 2134 (G>A) | G719S | 3 (2.5%) |
| Point mutation | 18 | 2155 (G>A) | G719A | 9 (7.6%) |
| Deletion | 19 | 235-2249del (GGA ATT AAG AGA AGC) | delE746-A750 | 39 (33.4%) |
| Del/Ins | 19 | 2235-2252del (GGA ATT AAG AGA AGC insCA) | L747-6751insP | 10 (8.5%) |
| Del/Ins | 19 | 2235-2252del (GGA ATT AAG AGA AGC insAAT) | delE746-T751insI | 5 (4.2%) |
| Del/Ins | 19 | 2235-2258del (GGA ATT AAG AGA AGC insAAT CCA) | delE746-A750insIP | 1 (0.8%) |
| Del/Ins | 19 | 2235-2249del (GGA ATT AAG AGA AGC insAGA) | delL747-P753insS | 3 (2.5%) |
| Del/Ins | 19 | 2235-2258del (GGA ATT AAG AGA AGC insAAT) | delE746-A750insI | 3 (2.5%) |
| Del/Ins | 19 | 2235-2258del (GGA ATT AAG AGA AGC insCCA) | delA746-A750insP | 1 (0.8%) |
| Del/Ins | 19 | 2235-2258del (GGA AAT AAG AGA AGC insCAA) | delL747-T751insQ | 1 (0.8%) |
| Point mutation | 20 | 2369 (C>T) | T790M | 3 (2.5%) |
| Point mutation | 21 | 2573 (T>G) | L858R | 10 (8.5%) |
| Point mutation | 21 | 2582 (T>A) | L861Q | 29 (24.6%) |
(B) Types of KRAS mutations in Turkish NSCLC patients.
| Mutation Types | Codon | Nucleotide Number | Amino Acid Changes | Mutations |
|---|---|---|---|---|
| Point mutation | 12 | 34 (G>A) | G12S | 10 (12.7%) |
| Point mutation | 12 | 34 (G>T) | G12C | 8 (10.1%) |
| Point mutation | 12 | 35 (G>A) | G12D | 6 (6.7%) |
| Point mutation | 12 | 35 (G>T) | G12V | 20 (25.2%) |
| Point mutation | 12 | 35 (G>A) | G12A | 1 (1.3%) |
| Point mutation | 13 | 37 (G>A) | G13D | 1 (1.3%) |
| Point mutation | 61 | 182 (A>G) | Q61R | 18 (22.8%) |
| Point mutation | 61 | 183 (A>C) | Q61H | 15 (19.0%) |
Detailed clinicopathological characteristics of patients with EGFR and KRAS mutations.
| Characteristics | Patients | EGFR Mutations (32.33%) | KRAS Mutations (25.0%) | EGFR and KRAS Mutations (6.6%) | |||
|---|---|---|---|---|---|---|---|
| ( | [+] ( | [–] ( | [+] ( | [–] ( | [+] ( | [–] ( | |
| Age: | |||||||
| ≤62 years | 148 | 50 (32.9%) | 102 (67.1%) | 32 (21.1%) | 120 (78.9%) | 7 (4.6%) | 145 (95.4%) |
| ≥62 years | 152 | 47 (31.8%) | 101 (68.2%) | 43 (29.1%) | 105 (70.9%) | 13 (8.8%) | 135 (91.2%) |
| Gender: | |||||||
| males | 238 | 67 (28.2%) | 171 (71.8%) | 63 (26.5%) | 174 (73.5%) | 16 (6.7%) | 222 (93.3%) |
| females | 62 | 30 (48.3%)a | 32 (51.7%) | 12 (19.4%) | 50 (80.6%) | 4 (6.5%) | 58 (93.5%) |
| Smoking habit: | |||||||
| smoker | 233 | 59 (26.5%) | 164 (73.5%) | 58 (26.0%) | 165 (74.0%) | 11 (4.9%) | 212 (88.4%) |
| never smoked | 77 | 38 (49.4%)a | 39 (50.6%) | 17 (22.0%) | 60 (78.0%) | 9 (11.6) | 68 (88.4%) |
| Histological type: | |||||||
| adenocarcinoma | 228 | 77 (33.7%)a | 151 (66.3%) | 55 (24.1%) | 173 (75.9%) | 16 (7.0%) | 212 (93.0%) |
| squamous | 62 | 13 (21.0%) | 49 (79.0%) | 18 (29.0%) | 44 (71.0%) | 2 (3.2%) | 60 (96.8%) |
| other | 10 | 7 (70.0%) | 3 (30.0%) | 2 (20.0%) | 8 (80.0%) | 2 (20.0%) | 8 (80.0%) |
| Stage: | |||||||
| early (I; II; IIIA) | 70 | 18 (25.7%) | 52 (74.3%) | 16 (22.8%) | 54 (77.2%) | 2 (2.8%) | 68 (97.2%) |
| advanced (IIIB; IV) | 230 | 79 (34.3%) | 151 (65.7%) | 59 (25.6%) | 171 (74.4%) | 18 (7.8%) | 212 (92.2%) |